We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Drug companies Teva Pharmaceutical, Endo Pharmaceuticals and Teikoku Pharma have signed four settlement agreements with the State of California to resolve allegations regarding pay-for-delay deals to prevent cheaper, generic medicines from entering the ma
Mylan Inc. and Mylan Specialty L.P. have agreed to pay $465 million to resolve claims that they violated the False Claims Act by knowingly misclassifying EpiPen as a generic drug to avoid paying rebates owed primarily to Medicaid, the Justice Department a